We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
AstraZeneca Diabetes Drug Combination Positive in Phase III
Read MoreHide Full Article
AstraZeneca plc (AZN - Free Report) announced positive results from a phase III combination trial evaluating the combination of its diabetes drugs Bydureon (exenatide extended-release) and Farxiga (dapagliflozin) for the treatment of patients with type II diabetes.
Anti-diabetes medicine Bydureon is a GLP-1 receptor agonist, whereas Farxiga is an SGLT-2 inhibitor.
The study achieved the primary endpoint, showing significant blood sugar reduction from baseline (as measured by HbA1c) in patients with type II diabetes, when treated with the combination of once-weekly exenatide and dapagliflozin, compared with the drugs alone in patients, who are inadequately controlled on metformin.
Duration-8 is a phase III, randomized, multi-center, double-blind, active-controlled trial. It was conducted over a 28-week treatment period, with an extension of two years, and enrolled approximately 700 patients from six countries. Eligible participants in the trial included adults with type II diabetes, who had uncontrolled HbA1c. The trial achieved the secondary endpoints as well, leading to a significant reduction in bodyweight and systolic blood pressure for the combination drug.
The combination of exenatide and dapagliflozin demonstrated similar rates of adverse events and serious events as the individual medicine treatment groups.
The results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes in Munich, Germany, and were also published in The Lancet Diabetes & Endocrinology.
AstraZeneca has been making significant progress with its pipeline. Promising pipeline candidates at the company include brodalumab (moderate-to-severe psoriasis), benralizumab (asthma and chronic obstructive pulmonary disease), tralokinumab (asthma), anifrolumab (systemic lupus erythematosus), roxadustat (anemia in patients with chronic kidney disease) and AZD3293 (Alzheimer’s disease, phase III).
AstraZeneca currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Cambrex Corporation and Johnson & Johnson (JNJ - Free Report) . While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
AstraZeneca Diabetes Drug Combination Positive in Phase III
AstraZeneca plc (AZN - Free Report) announced positive results from a phase III combination trial evaluating the combination of its diabetes drugs Bydureon (exenatide extended-release) and Farxiga (dapagliflozin) for the treatment of patients with type II diabetes.
Anti-diabetes medicine Bydureon is a GLP-1 receptor agonist, whereas Farxiga is an SGLT-2 inhibitor.
The study achieved the primary endpoint, showing significant blood sugar reduction from baseline (as measured by HbA1c) in patients with type II diabetes, when treated with the combination of once-weekly exenatide and dapagliflozin, compared with the drugs alone in patients, who are inadequately controlled on metformin.
Duration-8 is a phase III, randomized, multi-center, double-blind, active-controlled trial. It was conducted over a 28-week treatment period, with an extension of two years, and enrolled approximately 700 patients from six countries. Eligible participants in the trial included adults with type II diabetes, who had uncontrolled HbA1c. The trial achieved the secondary endpoints as well, leading to a significant reduction in bodyweight and systolic blood pressure for the combination drug.
The combination of exenatide and dapagliflozin demonstrated similar rates of adverse events and serious events as the individual medicine treatment groups.
The results were presented at the 52nd Annual Meeting of the European Association for the Study of Diabetes in Munich, Germany, and were also published in The Lancet Diabetes & Endocrinology.
AstraZeneca has been making significant progress with its pipeline. Promising pipeline candidates at the company include brodalumab (moderate-to-severe psoriasis), benralizumab (asthma and chronic obstructive pulmonary disease), tralokinumab (asthma), anifrolumab (systemic lupus erythematosus), roxadustat (anemia in patients with chronic kidney disease) and AZD3293 (Alzheimer’s disease, phase III).
ASTRAZENECA PLC Price
ASTRAZENECA PLC Price | ASTRAZENECA PLC Quote
Zacks Rank & Key Picks
AstraZeneca currently carries a Zacks Rank #3 (Hold). Some better-ranked stocks in the health care sector include ANI Pharmaceuticals, Inc. (ANIP - Free Report) , Cambrex Corporation and Johnson & Johnson (JNJ - Free Report) . While both ANI Pharmaceuticals and Cambrex Corporation sport a Zacks Rank #1 (Strong Buy), Johnson & Johnson carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Confidential from Zacks
Beyond this Analyst Blog, would you like to see Zacks' best recommendations that are not available to the public? Our Executive VP, Steve Reitmeister, knows when key trades are about to be triggered and which of our experts has the hottest hand. Click to see them now>>